Latest Breaking News On - Acta pharmacologica sinica - Page 4 : vimarsana.com

VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate COVID-19 in High Risk Patients Reaches Primary Endpoint | Comunicados | Edición USA

VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate COVID-19 in High Risk Patients Reaches Primary Endpoint | Comunicados | Edición USA
efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoJunshi bioscienceJunshi biosciencesZhi liActa pharmacologica sinicaIr teamCentral asian centerChinese academy of sciencesXinjiang technical institute of physicsVigonvita life sciences co ltdPr teamInstitute of microbiology the chinese academyShanghai institute of materia medicaWuhan institute of virologyShanghai junshi biosciences co ltd

Junshi Biosciences: VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate COVID-19 in High Risk Patients Reaches Primary Endpoint

the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint VV116 has a favorable safety profile and fewer adverse events than PAXLOVID SHANGHAI

United statesJunshi bioscienceJunshi biosciencesZhi liActa pharmacologica sinicaIr teamCentral asian centerChinese academy of sciencesXinjiang technical institute of physicsVigonvita life sciences co ltdPr teamShanghai institute of materia medicaWuhan institute of virologyShanghai junshi biosciences co ltdDevelopment chinese academy of sciences chinaShanghai institute